MedTrace Logo

Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer

NCT05059782 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2021-09-28

No results posted yet for this study

Summary

In this study, The researchers sought to explore the efficacy and safety of involving field radiotherapy in the oligo-metastatic/recurrent/refractory ovarian cancer patients among different groups which include drug therapy alone, radiotherapy alone, and drug therapy plus radiotherapy by inviting clinical multi-center participation.

Conditions

  • Ovarian Cancer
  • Neoplasm, Ovarian
  • Ovarian Neoplasm
  • Ovary Neoplasms
  • Neoplasm, Ovary
  • Neoplasms, Ovary
  • Ovary Neoplasm
  • Neoplasms, Ovarian
  • Ovary Cancer
  • Cancer, Ovarian Stromal
  • Cancers, Ovary
  • Ovary Cancers
  • Cancer, Ovarian
  • Cancers, Ovarian
  • Ovarian Cancers
  • Cancer of Ovary
  • Cancer of the Ovary

Interventions

DRUG

chemotherapy, targeted therapeutics, immunotherapy

Chemotherapy drugs ,targeted drugs or Immune checkpoint inhibitors are taken throughout the body or a combination of these drugs according to clinical needs is performed when necessary.

RADIATION

IFRT, IMRT or SBRT

IFRT（involving field radiotherapy） IMRT （ intensity modulated radiation therapy） SBRT （stereotactic body radiation therapy）

Sponsors & Collaborators

  • Xi'an Jiaotong University

    lead OTHER

Principal Investigators

  • Zi Liu, Ph.d · First Affiliated Hospital Xi'an Jiaotong University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-10
Primary Completion
2023-02-28
Completion
2024-09-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05059782 on ClinicalTrials.gov